Clinical Trial Update: Impact of Dysbiosis-inducing Drugs on Effectivity of Immune Checkpoint Inhibitor in Non-small Cell Lung Cancer Patients

View source ↗

Summary

A clinical trial update describes a study investigating whether dysbiosis-inducing drugs influence the effectiveness of an immune checkpoint inhibitor in Non-sm…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: University Hospital, Strasbourg, France | Conditions: Dysbiosis | Status: RECRUITING